Journal
LUNG CANCER
Volume 84, Issue 1, Pages 36-38Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2014.01.023
Keywords
EGFR-mutation; BRAF-mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors
Categories
Funding
- South-Eastern Norway Regional Health Authority
- GlaxoSmithKline Norway
Ask authors/readers for more resources
Objectives: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. Material and methods: NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. Results: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 23% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). Conclusion: BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available